| Methods |
Multicentre, single‐blind, placebo‐controlled
Randomisation method not stated
ITT analysis |
| Participants |
Europe
85 patients: T1: 10, T2: 10, T3: 20, C: 45
Mean age: T1, T2, T3: 68 years, C: 65 years
39 male and 46 female
Inclusion: IS in the anterior circulation
100% CT scans
Enrolment within 18 hours |
| Interventions |
T1: 25 mg/kg 10% DCLHb
T2: 50 mg/kg 10% DCLHb
T3: 100 mg/kg 10%DCLHb
C: equal volume of 0.9% normal saline given every 6 hours for 73 hours
Rx: 3 days |
| Outcomes |
Rankin at 3 months
BP and heart rate measured every 15 minutes for approximately 72 hours |
| Notes |
— |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Probably done |
| Allocation concealment? |
Unclear risk |
Unclear from publications |
| Blinding? |
High risk |
Study was single‐blinded because of the prominent colour of the drug and the difficulty in manufacturing a proper placebo |
| Completeness of follow‐up |
Unclear risk |
Unclear from publications |
